|
|
|
|
|
|
|
Highlights from the 2024 American Society for Radiation Oncology Annual Meeting |
|
|
|
|
| The RAVENS Phase 2 Randomized Trial: Outcomes of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS
|
| Ana Kiess, MD, PhD
|
| Ana Kiess presents results from the RAVENS phase 2 randomized trial, which assessed stereotactic ablative radiotherapy (SABR) with or without radium-223 in oligometastatic prostate cancer. The trial found no significant difference in progression-free survival between the two groups, suggesting that adding radium-223 did not delay disease progression.
|
|
|
|
|
|
| MRI-Guided Versus CT-Guided SBRT for Prostate Cancer: 2-Year Outcomes from the MIRAGE Randomized Clinical Trial
|
| Amar Kishan, MD
|
| Amar Kishan presents the two-year outcomes from the MIRAGE randomized trial comparing MRI-guided vs. CT-guided SBRT for prostate cancer. The results showed that MRI-guided SBRT significantly reduced grade 2+ genitourinary and gastrointestinal toxicity compared to CT-guided SBRT, and also led to better outcomes in urinary, bowel, and sexual health domains. The findings highlight the sustained benefits of MRI guidance in reducing toxicity and improving patient-reported quality of life after prostate SBRT.
|
|
|
|
|
|
| EMPIRE-2: Volumetric Changes and Acute Toxicity with 68Ga PSMA Versus 18F-Fluciclovine PET/CT-Guided Post-Prostatectomy Radiation: Final Analysis of a Randomized Trial
|
| Vishal Dhere, MD
|
| Vishal Dhere presents final results from the EMPIRE-2 trial, comparing 68Ga PSMA and 18F-Fluciclovine PET/CT-guided post-prostatectomy radiation in patients with biochemical recurrence. Both imaging methods increased radiation target volumes, but significantly more 18F-Fluciclovine patients received prostate bed boosts. Acute toxicity was mild in both arms, with no significant differences in grade 2+ genitourinary or gastrointestinal toxicity between the groups.
|
|
|
|
|
|
| Dose Escalated Pelvic Lymph Node IMRT with a Simultaneous Hypofractionated Boost to the Prostate for NCCN Very-High Risk Adenocarcinoma of the Prostate, a Prospective Trial |
| William Hall, MD |
| William Hall presents results from a prospective phase II trial evaluating dose-escalated pelvic lymph node Intensity-Modulated Radiation Therapy (IMRT) with a simultaneous hypofractionated boost to the prostate for NCCN very-high-risk non-metastatic prostate cancer. The study enrolled 80 patients, treating pelvic lymph nodes with 56 Gy over 28 fractions and boosting the prostate with 70 Gy over 28 fractions. |
|
|
|
|
|
| F-SHARP: Initial Results of a Multi-Institutional Phase 1/2 Trial of Focal Dose-Escalated Salvage HDR Brachytherapy for Radiorecurrent Prostate Cancer |
| Abhishek Solanki, MD |
| Abhishek Solanki presents the initial results of the F-SHARP trial, a multi-institutional phase I/II study of focal dose-escalated salvage HDR brachytherapy for radiorecurrent prostate cancer. The study showed that this approach is safe and effective, with no grade 3 or higher toxicities reported over a median follow-up of 32.3 months. Three-year outcomes included 61% biochemical progression-free survival, 89% metastasis-free survival, and 93% freedom from ADT, with most toxicities being mild or moderate. |
|
|
|
|
|
| Focal MR-Guided HDR Brachytherapy Boost Combined with SBRT for Localized Prostate Cancer
|
| Carlton Johnny, MD
|
| Carlton Johnny presents the results from a study on focal MR-guided HDR brachytherapy combined with SBRT for localized prostate cancer. Early outcomes demonstrated high biochemical control rates, with 96.5% overall at 3 years, and acceptable tolerability, with only mild-to-moderate genitourinary and gastrointestinal toxicities. The study suggests that this combined approach is safe and effective, though long-term follow-up is needed to fully assess oncological outcomes and toxicity.
|
|
|
|
|
|
| SBRT Versus Conventional Fractionation EBRT Boost for Unfavorable Intermediate and High-Risk Prostate Cancer. Early Results of PBS phase II Randomized Trial
|
| Andre Gouveia, MD
|
| Andre Gouveia presents the early results from the PBS phase II trial comparing stereotactic body radiotherapy boost to conventional fractionation external beam radiotherapy boost for unfavorable intermediate and high-risk prostate cancer. At 3 months post-treatment, there were no significant differences between SBRT and EBRT boost groups in patient-reported quality of life (EPIC scores), IPSS, or toxicity rates.
|
|
|
|
|
|
|
|
|
|
|
